Is NTLA a Buy? What to Consider in 2026
Short answer
The bull case for Intellia Therapeutics (NTLA) rests on Positive Late-Stage Lonvo-z Data in Hereditary Angioedema: In 2026 Intellia reported positive Phase 3 HAELO results for lonvo-z in hereditary angioedema, including an approximately 87 percent reduction in mean monthly attacks versus placebo, with a majority of treated patients reported as attack-free over the efficacy period. Revenue is Collaboration revenue only (e.g., Regeneron); no product revenue yet. If you believe that thesis holds, the real questions become position sizing and overlap, not timing. The main risk to that view: Intellia is pre-revenue from products, deeply unprofitable, and its value depends on binary clinical and regulatory outcomes; a single failed trial, safety signal, or FDA setback for lonvo-z or nex-z could sharply reduce the stock's value. Whether NTLA is a buy comes down to whether you believe the thesis. This is informational, not a recommendation, and Walnut is not an investment adviser.
Intellia Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in Cambridge, Massachusetts, developing genome-editing therapies based on CRISPR/Cas9. Its core differentiator is a proprietary in vivo platform that delivers the editing machinery directly into the body, typically the liver, using lipid nanoparticles, so that a single dose can permanently inactivate or modify a disease-causing gene without removing cells from the patient. This contrasts with ex vivo approaches that edit cells outside the body and reinfuse them. The company is pre-revenue from products and currently records only collaboration revenue from partners; it funds operations through its cash reserves and periodic capital raises. Intellia was co-founded in 2014, drawing on foundational CRISPR research associated with Nobel laureate Jennifer Doudna, and went public on the Nasdaq in 2016. Its two most advanced wholly described programs are lonvoguran ziclumeran (lonvo-z, formerly NTLA-2002) for hereditary angioedema and nexiguran ziclumeran (nex-z, formerly NTLA-2001) for transthyretin (ATTR) amyloidosis, the latter developed in collaboration with Regeneron Pharmaceuticals. In 2025 the company prioritized these late-stage assets through a strategic reorganization. As of mid-2026, lonvo-z had reported positive Phase 3 HAELO results and entered rolling FDA biologics license application review, while the nex-z Phase 3 MAGNITUDE and MAGNITUDE-2 trials in ATTR were advancing after the FDA lifted earlier clinical holds.
What's the case for buying NTLA?
Positive Late-Stage Lonvo-z Data in Hereditary Angioedema
In 2026 Intellia reported positive Phase 3 HAELO results for lonvo-z in hereditary angioedema, including an approximately 87 percent reduction in mean monthly attacks versus placebo, with a majority of treated patients reported as attack-free over the efficacy period. The data were published in the New England Journal of Medicine and presented at EAACI 2026. The company has begun a rolling FDA biologics license application, positioning lonvo-z as a potential one-time treatment with a possible U.S. launch in 2027.
In Vivo CRISPR Platform
Intellia's central asset is its in vivo editing platform, which aims to make a single-dose, durable genetic change inside the patient's body rather than through cells edited in a lab. If validated across multiple programs, this approach could be applied to a range of genetic and acquired diseases. The same delivery and editing technology underlies both lead candidates, so platform validation in one indication carries read-through to the broader pipeline.
Regeneron Partnership and Nex-z in ATTR Amyloidosis
The nex-z program for ATTR amyloidosis is developed with Regeneron Pharmaceuticals, which shares development costs and provides a large-pharma partner. In early 2026 the FDA lifted clinical holds on the Phase 3 MAGNITUDE (cardiomyopathy) and MAGNITUDE-2 (polyneuropathy) trials, with MAGNITUDE-2 enrollment targeted for the second half of 2026. ATTR amyloidosis is a large and growing market currently served by approved stabilizer and silencer drugs from other companies.
Large Addressable Disease Areas
Both lead programs target serious diseases with meaningful patient populations and high unmet need where a single-dose therapy could be differentiated from chronic treatments. Hereditary angioedema patients currently rely on lifelong prophylaxis, and ATTR amyloidosis is an underdiagnosed, progressive condition. A durable one-time editing approach, if approved and adopted, could address both the clinical burden and the cumulative cost of chronic therapy, though commercial success is not assured.
What are the risks to NTLA?
Intellia is pre-revenue from products, deeply unprofitable, and its value depends on binary clinical and regulatory outcomes; a single failed trial, safety signal, or FDA setback for lonvo-z or nex-z could sharply reduce the stock's value. The company burns roughly $90 million to $100 million per quarter and has repeatedly raised equity to extend its runway, so existing shareholders face ongoing dilution risk before any product profit materializes. Even with positive data, regulatory approval, reimbursement, and commercial adoption of a novel one-time gene-editing therapy are uncertain and could take years. The company also competes with better-capitalized CRISPR and gene-editing peers, with RNA-interference and stabilizer drugs already approved in ATTR, and with established prophylaxis options in hereditary angioedema.
How is NTLA valued? (as of June 27, 2026 (data reflects most recently available reports through mid-2026))
- Cash and Marketable Securities: ~$517 million (as of March 31, 2026), plus ~$207 million gross from an April 2026 equity offering
- Stated Cash Runway: Expected to fund operations at least into 2028
- Net Loss (Q1 2026): ~$96 million (versus ~$114 million in Q1 2025)
- Revenue: Collaboration revenue only (e.g., Regeneron); no product revenue yet
- Market Capitalization: ~$1.7 billion (June 2026, moves sharply on clinical news)
- P/E Ratio (TTM): Negative (not meaningful; company is unprofitable)
Because Intellia has no product profits and only collaboration revenue, traditional earnings-based valuation multiples like P/E are negative and not analytically useful. The stock is better evaluated on its cash runway relative to its burn rate, the probability and timing of regulatory approval for lonvo-z and nex-z, and the risk-adjusted commercial potential of those programs. The April 2026 equity raise extended the stated runway at least into 2028, but pre-profit biotechs of this type typically require additional capital before reaching sustained profitability, so dilution and the binary nature of trial readouts are central to any valuation view.
How do you decide if NTLA is a buy?
Rather than asking whether NTLA is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold NTLA indirectly through an index or sector ETF before adding more.
For the full picture, see the NTLA stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about NTLA against your real portfolio and see your actual exposure before deciding.
The bottom line on NTLA
The bottom line: Intellia Therapeutics's story right now is Positive Late-Stage Lonvo-z Data in Hereditary Angioedema, with revenue at Collaboration revenue only (e.g., Regeneron); no product revenue yet. If you believe that narrative continues, the call is about sizing NTLA sensibly and checking overlap with what you own; if you doubt it (the risk: intellia is pre-revenue from products, deeply unprofitable, and its value depends on binary clinical and regulatory outcomes; a single failed trial, safety signal, or FDA setback for lonvo-z or nex-z could sharply reduce the stock's value.), it is not for you. Decide from the thesis, not the ticker. Walnut is not an investment adviser.
Build a basket around NTLA with Walnut
Use Intellia Therapeutics as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is NTLA a good stock to buy right now?
+
The case for Intellia Therapeutics right now is Positive Late-Stage Lonvo-z Data in Hereditary Angioedema, with revenue at Collaboration revenue only (e.g., Regeneron); no product revenue yet. If you believe that thesis holds, NTLA is a way to own it and the real questions are sizing and overlap, not timing; the main risk to that view is intellia is pre-revenue from products, deeply unprofitable, and its value depends on binary clinical and regulatory outcomes; a single failed trial, safety signal, or FDA setback for lonvo-z or nex-z could sharply reduce the stock's value. So it comes down to whether you believe the thesis. Walnut is not an investment adviser and this is not a recommendation.
What does Intellia Therapeutics do?
+
Intellia Therapeutics, Inc.
What are the main risks of NTLA?
+
Intellia is pre-revenue from products, deeply unprofitable, and its value depends on binary clinical and regulatory outcomes; a single failed trial, safety signal, or FDA setback for lonvo-z or nex-z could sharply reduce the stock's value. The company burns roughly $90 million to $100 million per quarter and has repeatedly raised equity to extend its runway, so existing shareholders face ongoing dilution risk before any product profit materializes. Even with positive data, regulatory approval, reimbursement, and commercial adoption of a novel one-time gene-editing therapy are uncertain and could take years. The company also competes with better-capitalized CRISPR and gene-editing peers, with RNA-interference and stabilizer drugs already approved in ATTR, and with established prophylaxis options in hereditary angioedema.
What does Intellia do?
+
Intellia Therapeutics is a clinical-stage biotechnology company that develops genome-editing medicines using CRISPR/Cas9. Its specialty is in vivo editing, delivering the editing machinery directly into the body so a single dose can permanently alter a disease-causing gene. Its two lead programs are lonvo-z for hereditary angioedema and nex-z for ATTR amyloidosis, the latter partnered with Regeneron Pharmaceuticals.
Is NTLA a good stock to buy right now?
+
That depends entirely on an investor's risk tolerance and time horizon, and this is not advice. The bull case is positive Phase 3 lonvo-z data, an active FDA filing, a Regeneron-partnered ATTR program, and a validated in vivo platform. The bear case is that NTLA is pre-revenue, unprofitable, burns roughly $90 to $100 million per quarter, and depends on binary trial and regulatory outcomes that can move the stock sharply.
Is NTLA profitable?
+
No. Intellia is a clinical-stage, pre-revenue company that records only collaboration revenue and has no approved products generating sales. It reported a net loss of roughly $96 million in the first quarter of 2026 and funds operations through cash reserves and periodic equity raises. Profitability would depend on successfully bringing lonvo-z, nex-z, or another program to market, which has not yet happened.
Does NTLA pay a dividend?
+
No. Intellia Therapeutics does not pay a dividend. As an unprofitable, pre-commercial biotech, the company directs all of its capital toward clinical development and operations rather than returning cash to shareholders. Investors seeking dividend income would need to look elsewhere in the healthcare or broader market, as any return from NTLA would have to come from share-price appreciation.
Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell NTLA; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.